Amerimmune Pharmaceuticals, Inc.

6 articles about Amerimmune Pharmaceuticals, Inc.

• Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration

  1/18/2023

  Amerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19.

• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.
• 

  Clinical Catch-Up: August 16-20

  8/23/2021

  It was another busy week in clinical trial news. Here’s a look.

• Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

  8/16/2021

  Histogen Inc. and its partner Amerimmune, LLC today announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy.

• 

  Clinical Catch-Up: June 21-25

  6/28/2021

  It was a busy week for clinical trial news. Here’s a look.
• 

  Biopharma Update on the Novel Coronavirus: October 27

  10/27/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.